Core Insights - Istaroxime is a first-in-class dual-mechanism therapy aimed at treating acute heart failure (AHF) and has shown positive results in Phase 2 studies [3] - The United States Patent and Trademark Office has granted a patent for istaroxime, which will provide protection until 2039 if approved for AHF [1][2] - Windtree Therapeutics is focused on becoming a revenue-generating company across multiple growing industries [4] Company Overview - Windtree Therapeutics, Inc. is a diversified company with a focus on revenue generation and profitability in various industries [4] - The company is advancing istaroxime towards Phase 3 readiness for cardiogenic shock and AHF [2] Product Details - Istaroxime improves both systolic and diastolic cardiac function, increasing myocardial contractility and facilitating myocardial relaxation [3] - Clinical data indicates that istaroxime can significantly enhance cardiac function and blood pressure without raising heart rate or causing significant cardiac rhythm disturbances [3]